Processa Pharmaceuticals (PCSA) Non-Current Debt (2012 - 2021)
Processa Pharmaceuticals' (PCSA) quarterly Non-Current Debt came in at $17571.0 in Q1 2021, down 97.82% YoY from $805000.0 in Q1 2020, and down 60.85% on a QoQ basis from $44885.0 in Q4 2020.
Processa Pharmaceuticals (PCSA) Non-Current Debt (2012 - 2021) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 10 years of Non-Current Debt data on file, last reported at $17571.0 in Q1 2021.
- Quarterly Non-Current Debt fell 97.82% year-over-year to $17571.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $17571.0 (down 97.82% YoY) and the FY2020 annual result came in at $44885.0, down 94.42% from the prior year.
- Non-Current Debt fell to $17571.0 in Q1 2021, from $44885.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $2.6 million in Q4 2017 to a low of $17571.0 in Q1 2021.
- A 5-year average of $583767.2 and a median of $229990.0 in 2017 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2017 — Non-Current Debt surged 1021.84% — and 2021, when it slumped 97.82%.
- Tracing PCSA's Non-Current Debt over 5 years: stood at $2.6 million in 2017, then sank by 91.09% to $230000.0 in 2018, then jumped by 250.0% to $805000.0 in 2019, then sank by 94.42% to $44885.0 in 2020, then plunged by 60.85% to $17571.0 in 2021.
- The last three Non-Current Debt figures came in at $17571.0 (Q1 2021), $44885.0 (Q4 2020), and $805000.0 (Q3 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 17,571.00 |
| Dec 31, 2020 | 44,885.00 |
| Sep 30, 2020 | 805,000.00 |
| Jun 30, 2020 | 90,256.00 |
| Mar 31, 2020 | 805,000.00 |
| Dec 31, 2019 | 805,000.00 |
| Dec 31, 2018 | 230,000.00 |
| Dec 31, 2017 | 2.58 Mn |
| Jun 30, 2017 | 229,980.00 |
| Mar 31, 2017 | 229,980.00 |
| Dec 31, 2016 | 229,980.00 |
| Sep 30, 2016 | 229,980.00 |
| Jun 30, 2016 | 229,980.00 |
| Mar 31, 2016 | 1.38 Mn |
| Dec 31, 2015 | 1.37 Mn |
| Sep 30, 2015 | 27,507.00 |
| Jun 30, 2015 | 104,948.00 |
| Mar 31, 2015 | 229,980.00 |
| Dec 31, 2014 | 360,232.00 |
| Sep 30, 2014 | 149,413.00 |